Phase I study of COM-701 in patients with advanced solid tumors

Trial Profile

Phase I study of COM-701 in patients with advanced solid tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs COM 701 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Compugen
  • Most Recent Events

    • 27 Apr 2018 U.S. Food and Drug Administration requested Compugen to provide additional CMC information in support of its IND application for COM701 (initially submitted in late March 2018) and FDA also informed that the IND application review can be completed and the application can be taken off clinical hold once the requested information is provided, according to a Compugen media release.
    • 05 Apr 2018 According to a Bayer media release, this first in human study is expected to start in 2018.
    • 21 Feb 2018 According to a Compugen Ltd. media release, the company is finalizing their protocol and IND application for COM701,and are on track to file the IND with the FDA, as planned, towards the end of the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top